Answers are grounded in this paper and cite their sources.
Assessment of CEA-specific T-cell responses may provide clinically relevant information for predicting treatment response and prognosis in colorectal cancer, but clinical translation has been hindered by incomplete epitope mapping and the lack of standardized, broadly applicable immune-monitoring assays. CD8 + T-cell epitopes in CEA were systematically screened using in silico prediction, peptide-PBMC co-culture, competitive binding assays, and HLA-transgenic mouse immunization. Validated epitopes were used to establish an IFN-γ ELISpot assay for quantifying CEA-specific T-cell responses in dMMR/MSI-H CRC patients receiving anti-PD-1 therapy, including a derivation cohort ( n = 80) and an independent test cohort ( n = 21), with objective response and 12 month PFS as clinical endpoints. We validated 59 immunogenic CD8 + T-cell epitopes restricted by 13 HLA-A, 15 HLA-B, and 14 HLA-C allotypes and covering > 90%, 70%, and 90% of Northeast Asian populations, respectively. In the derivation cohort, the post-/pre-treatment CEA-specific T-cell fold predicted objective response (AUC = 0.866; cut-off = 2.15) and 12 month PFS (AUC = 0.851; cut-off = 2.05), outperforming KRAS/BRAF status and early serum CEA decline. Based on these cut-offs, a unified fold cut-off of 2.1 was predefined for validation and retained predictive performance in the independent test cohort, with AUCs of 0.809 and 0.824 for objective response and 12 month PFS, respectively. We established an ELISpot assay to quantify CEA-specific T-cell responses and found that this peripheral blood readout may serve as a clinically informative biomarker for stratifying response and PFS after anti-PD-1 therapy in dMMR/MSI-H CRC.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: